(locally recurrent after oesophagogastrectomy in one case), and in four due to spread from tumours elsewhere. The patients were told of the various treatment options and the potential hazards of the procedure. All gave informed consent. Before and after endoprosthesis placement, dysphagia was scored on a scale similar to that of Mellow and Pinkas 9 : 0 =normal; 1 =can swallow some but not all solids; 2 = can swallow semisolids; 3 = liquids only; 4 = unable to swallow liquids. They were followed up with regular outpatient review and communication with their general practitioners.
INTRODUCTION

METHODS
Self-expanding metallic stents have been employed successfully for vascular, urethral, and biliary strictures. In a prospective study we examined the efficacy of the 16 mm Wallstent for palliation of malignant dysphagia.
Eight patients with severe dysphagia due to advanced primary (four) or secondary (four) oesophageal malignant disease were recruited and nine Wallstents were inserted (one patient required two). Dysphagia was reduced in all but one patient, who died after oesophageal perforation; a second patient had a self-limiting bout of haematemesis. Two patients required subsequent treatment for tumour ingrowth but five had no further palliative therapy from stent insertion to time of death.
With careful patient selection and skilful application, a 16 mm self-expanding metal endoprosthesis affords effective palliation in malignant oesophageal obstruction.
In advanced malignant disease of the oesophagus the primary aim of treatment is to correct dysphagia and prevent aspiration pneumonia. In many centres surgical resection is still the main method of palliation, but various alternative approaches are adopted including external beam and intraluminal radiotherapy, chemotherapy, laser recanalization, bipolar diathermy coagulation, and alcohol injection 1,2. Endoscopic intubation is a cost-effective, efficient, and durable palliative procedure but insertion of standard tubes carries a 5%-8% risk of perforation and blockage is troublesome in the long term 3 . Self-expanding metallic stents, successfully used for vascular, urethral, and biliary strictures, have been tried in malignant dysphagia hut experience is limited4-8. We have assessed this technique prospectively in a small series. Perforation T/S=Technical success; SI-pre=swallowing index prior to stent insertion; SI-post=swallowing index following stent insertion; oes=oesophageal; ca-carcinorna: recerecurrence checked endoscopically and by plain radiographs of the chest. Patients remained in hospital until they were on a normal diet and comfortable. They were not asked to avoid specific foods but were advised to masticate thoroughly, and to take carbonated drinks after eating.
RESULTS
Results are summarized in Table 1 . The procedure was well tolerated and correct stent placement was achieved in seven patients; one patient required two stcnts in series to relieve dysphagia. In the one failure the patient had a long tumour stenosis extending from 32 em to the oesophagogastric junction. Despite dilatation to 42 FG the stent was misplaced in the upper third of the oesophagus proximal to the stricture. All other patients had an improvement in swallowing by two or more grades. The median in-patient stay was 6 days (range 2-12). In a follow-up period of 15 months all but one patient died (the remaining patient is alive and well). Median survival was 98 days (range 9--488+).
Complications
One patient had a mild haematemesis after the procedure, managed conservatively. The patient in whom the stent was misplaced developed mediastinitis and died 9 days after stent insertion. At necropsy there was a large extrinsic tumour mass eroding the lower third of the oesophagus. The stent protruded proximally from the stricture and there was a small perforation at the proximal tumour margin. Two patients developed recurrent dysphagia requiring further endoscopic procedures to treat tumour ingrowth into the endoprosthesis (one was treated by dilatation and injection of tumour with absolute alcohol on two occasions; the other required laser ablation on one occasion 14 months after initial stent insertion). There were no episodes of food impaction or stent migration.
DISCUSSION
Of the palliative treatments for malignant dysphagia, endoscopic intubation and laser ablation therapy have been scrutinized closely and are seen by many as the gold standard. Endoscopic intubation will relieve dysphagia in 90% of cases, but despite modifications of technique and the delivery system it is painful and frequently requires general anaesthesia. It also carries substantial morbidity (5%-34%) and mortality (16%). Pharyngo-oesophageal perforation and tube migration with recurrent dysphagia (20%) are the principal complications 10-12. Initial trials of laser ablation were encouraging, but this treatment is expensive and has serious complications in up to 9% of cases12,13. The major limitations are its poor longterm efficacy (around 60%) and the fact that two to five treatments are needed to establish luminal patency 14,15. Nevertheless, it has proved useful in combination with endoluminal and external beam radiation therapy and for relief of recurrent dysphagia after self-expanding stent insertion 16-18. Radiochemotherapy has met with limited success, improving swallowing in only 60% of patients and having serious side-effects19.
The main advantage of the self-expanding metallic stent is its ease of insertion and consequently low complication rate S ,6,8. There are two major caveats. First, it has largely been the domain of the interventional radiologist and gastroenterologist. If the technique is to be adopted by the thoracic surgeon, proper training and supervision are essential since misplacement of an endoprosthesis is catastrophic: stent retrieval is difficult and hazardous if not impossible. Second, with the increasing application of this technique patients presenting de novo with oesophageal carcinoma may not be properly evaluated regarding resectabilty of the tumour.
In our series we were cautious about early discharge but it is possible that this procedure could be done in out-patients, offsetting the considerable initial cost of the endoprosthesis (£700). However, the technique may be cost-effective in its own right if it gives lasting relief of dysphagia with less need for further intervention/". Tumour ingrowth is the main long-term drawback, but this is usually manageable with laser ablative therapy. Silicone-covered prostheses have been tried, but tumour can still penetrate the covering and these stcnts tend to migrate 21 . In conclusion, we agree with others that self-expanding prostheses can give excellent palliation III malignant dysphagia. A final judgment must await comparison with other strategies in controlled trials.
